BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chi ...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chi ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of the company are up 13% so far today. The ...

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical ...

Group 1 - Vor Bio underwent a reverse stock split at a ratio of 20 for 1 to increase its per-share price by reducing the number of shares outstanding [1][6] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development for serious autoantibody-driven conditions [2][6] - Vor Bio plans to present 48-week clinical data from a Phase 3 study in China at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on October 29, 2025 [3][6] Group 2 - Vor Bio is participating in the Stifel 2025 Virtual Immunology and Inflammation Forum, engaging in a fireside chat and hosting virtual one-on-one investor meetings [4] - The current stock price of Vor Bio is $1.52, with a market capitalization of approximately $192.6 million and a trading volume of 4,701,878 shares [5]

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1][2] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [2][3] Clinical Study Details - Vor Bio announced 48-week clinical data from a Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis [1] - The study demonstrated a placebo-adjusted 4.83-point improvement in the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) at 24 weeks, which is the primary endpoint of the trial [3] Product Information - Telitacicept selectively inhibits BLyS (BAFF) and APRIL, two cytokines essential for B cell and plasma cell survival, thereby reducing autoreactive B cells and autoantibody production [3] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [4] Market Context - Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder affecting approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan [5] - There is a significant unmet need for new therapies that provide durable efficacy and a favorable safety profile for gMG patients [5] Upcoming Presentation - The clinical data will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on October 29, 2025 [1][2]

Summary of Vor Biopharma Conference Call Company Overview - **Company**: Vor Biopharma (NasdaqGS:VOR) - **New Direction**: The company is undergoing a transformation referred to as "Vor 2.0," focusing on a late-stage asset in immunology, telitacicept, licensed from RemeGen, a Chinese biotech firm [4][5] Key Points and Arguments Asset and Mechanism - **Telitacicept**: A dual BAFF/APRIL inhibitor that normalizes the immune system and provides durable efficacy in autoimmune diseases, addressing limitations of current therapies [4][5] - **Data**: Over 70,000 patients treated in China and around 3,000 in clinical trials, with proven efficacy across three indications and two additional PLAs being filed [4][5] - **Market Opportunity**: Targeting myasthenia gravis and Sjögren's disease, both of which have high unmet medical needs [5] Competitive Advantage - **Differentiation**: Telitacicept is the most advanced BAFF/APRIL inhibitor, closely resembling the wild type TACI receptor, which enhances its efficacy and safety [6][7] - **Holistic Approach**: The drug targets both upstream and downstream B-cell pathways, potentially offering a more comprehensive treatment compared to FCRN antagonists and complement inhibitors [10][11] Myasthenia Gravis (MG) Development - **Patient Population**: Approximately 90,000 patients in the U.S. with significant unmet medical needs despite existing therapies [10] - **Phase 3 Trial**: Previous trials showed unprecedented activity on the primary endpoint (MGADL), with long-term data indicating sustained benefits [11][12] - **Global Phase 3 Trial**: Currently enrolling patients, leveraging data from China while ensuring quality and replicability in Western populations [17][20] Sjögren's Disease Development - **Patient Demographics**: Affects around 300,000 patients in the U.S., predominantly women, with significant symptoms and high rates of underdiagnosis [23][24] - **Phase 2 Results**: Telitacicept has shown best-in-disease results in previous trials, with a focus on multi-component scoring systems [25][26] - **Market Potential**: High unmet medical need and potential for multiple therapies in the space, with telitacicept positioned as a leading candidate [28] Financial Overview - **Capital Structure**: As of June, Vor Biopharma has $190 million in cash, providing a runway into Q1 2027, sufficient to support ongoing studies [40] - **Equity Units**: 1.2 billion equity units fully diluted [40] Upcoming Catalysts - **Data Presentations**: Anticipated long-term data from the MG study at AANEM and phase 3 data for Sjögren's at a major rheumatology conference [41] - **IgA Data**: Upcoming presentation of phase 3 data from China, showcasing consistent efficacy across autoimmune diseases [41] Conclusion - **Strategic Focus**: Vor Biopharma aims to change the standard of care in autoimmune diseases through its innovative approach and strong pipeline, with a disciplined strategy for capital allocation and development opportunities [34][41]

Core Insights - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [2] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development [2] Event Participation - Vor Bio will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 [1] - The fireside chat will take place from 4:00-4:25 pm ET and will be available via live webcast and archived replay on the company's website [1]

Summary of Vor Biopharma (VOR) Conference Call - September 02, 2025 Company Overview - **Company**: Vor Biopharma (VOR) - **Key Asset**: Telitacicept (Teli), a BAFF inhibitor for autoimmune diseases - **Partnership**: RemeGen, a large Chinese biopharma company Industry Insights - **Market Dynamics**: - Significant licensing deals for Chinese assets in the biotech sector - China has a rapidly growing biotech industry, with a pipeline comparable to the U.S. [6][11] - China Health 2030 initiative aims to streamline regulatory processes and clinical trials [12] Core Points and Arguments - **Asset Strength**: - Teli is a dual BAFF and APRIL inhibitor, addressing unmet needs in autoimmune diseases [6][16] - Over 70,000 patients treated in China, providing a robust real-world data set [7][25] - Advanced late-stage product with extensive clinical trial data [7][15] - **Market Potential**: - Myasthenia Gravis (MG) is identified as a key indication with a projected U.S. market of $4 billion, expected to grow to $10 billion by 2030 [19] - Sjögren's syndrome is highlighted as a significant opportunity due to lack of targeted treatments [33] - **Competitive Landscape**: - Teli is positioned as the most advanced BAFF/APRIL inhibitor globally, with a strong safety profile and efficacy data [25][30] - The product aims to address the shortcomings of existing therapies, particularly FCRN inhibitors [26][30] - **Regulatory and Development Strategy**: - Plans to initiate a global Phase III trial for Sjögren's syndrome, already approved by the FDA [35][44] - Ongoing Phase III trial for MG with promising long-term data expected [47] Additional Important Insights - **Data Quality and Transferability**: - Concerns about the transferability of Chinese clinical data to global populations have diminished, with increasing confidence in data integrity [10][11] - The company emphasizes the quality of its partnership with RemeGen, which has strong manufacturing capabilities [13][30] - **Future Milestones**: - Key upcoming data releases include Phase III results for Sjögren's syndrome and long-term MG data [47][48] - The company has approximately $199 million in cash, positioning it well for upcoming trials [49] - **Geopolitical Considerations**: - The partnership with RemeGen is viewed positively despite geopolitical tensions, with a focus on mutual benefits in innovation and market access [53][55] - **Immunology Pipeline**: - There is a growing interest in immunology deals from China, with a significant number of innovative modalities in development [56][57] This summary encapsulates the key points discussed during the conference call, highlighting Vor Biopharma's strategic positioning, market opportunities, and future plans in the context of the evolving biotech landscape.

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [3] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [3] Leadership Appointment - Adi Osovsky, S.J.D. has been appointed as General Counsel, bringing 17 years of experience in corporate counsel and law firm roles within the biotechnology and pharmaceutical sectors [1][2] - Dr. Osovsky previously served as Executive Vice President and Head of Legal & Corporate Secretary at iTeos Therapeutics, overseeing corporate legal and compliance activities [2] - Her experience includes senior legal roles at Sarepta Therapeutics, where she supported corporate transactions and governance during a period of rapid growth [2] Strategic Importance - The appointment of Dr. Osovsky is seen as crucial for Vor Bio's growth, particularly as the company advances its late-stage clinical programs [2] - The CEO, Jean-Paul Kress, emphasized that Dr. Osovsky's expertise in governance, compliance, and strategic transactions will be invaluable for the company's future [2]